ModifiSite™ Farnesyltransferase Inhibitor Screening Kit (CAT#: ITS-1125-WB31)

Quantifies farnesyltransferase activity using a fluorescence method.

ModifiSite

Research-Grade Protein-Based Assay Development

The ModifiSite™ Farnesyltransferase Inhibitor Screening Kit provides a safe, non-radioactive fluorimetric platform for high-throughput screening of FTase inhibitors. This homogeneous "mix-incubate-measure" system enables rapid evaluation of drug modulators that target protein farnesylation, a critical process in oncology research. With a robust Z' factor and automated compatibility, it streamlines the identification of potent therapeutic candidates in drug discovery.

High Sensitivity & Precision: Employs a robust fluorescence-based format to detect subtle enzymatic shifts, ensuring reliable IC50 determination for potential inhibitors.
Streamlined Homogeneous Protocol: Optimized for "mix-and-read" workflows, eliminating tedious wash steps and reducing experimental variability across diverse throughput scales.
Validated Specificity: Precision-engineered components minimize interference from complex chemical libraries, providing high-fidelity results during primary and secondary screening phases.

Accelerating lead identification by quantifying FTase inhibition to streamline the development of targeted anti-cancer small molecule therapies.

Lead discovery, preclinical drug candidate validation, and enzymatic activity profiling during early-stage pharmacological development.

Enabling high-throughput screening of chemical libraries, characterization of novel inhibitors, and kinetic analysis of protein farnesylation across various biological matrices.

Internal performance validation using reference standards under defined assay conditions.

Protein farnesyltransferase (FTase) enzyme activity and inhibitory kinetics.

Fluorescence Detection (Ex 340 nm / Em 550 nm)

Chemical compounds

Oncology therapeutics, signal transduction, molecular pharmacology, cell cycle regulation, etc.